MediWound Ltd.
MDWD$223M
Micro CapNASDAQMedicinal Chemicals & Botanical Products🇺🇸North AmericaYAVNE111 employees
Drugs in Pipeline
8
Phase 3 Programs
4
Upcoming Catalysts
1
Next Catalyst
Dec 15, 2026
39wMarket Overview
Stock performance and key metrics
MDWD News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
DGD
Burn
Gel Vehicle
Thermal Burns
EscharEx (EX-03)
Venous Leg Ulcer (VLU)
NexoBrid
Thermal Burns
EscharEx
Hard to Heal Wounds
EscharEx (5% EX-02 formulation)
Venous Leg Ulcer
EscharEx (EX-02 formulation)
Venous Leg Ulcer
EscharEx 5% (EX-02 formulation)
Superficial Basal Cell Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DGD | Phase 3 | Burn | - | - |
Gel Vehicle | Phase 3 | Thermal Burns | - | - |
EscharEx (EX-03) | Phase 3 | Venous Leg Ulcer (VLU) | - | - |
NexoBrid | Phase 3 | Thermal Burns | - | - |
EscharEx | Phase 2 | Hard to Heal Wounds | - | - |
EscharEx (5% EX-02 formulation) | Phase 2 | Venous Leg Ulcer | - | - |
EscharEx (EX-02 formulation) | Phase 2 | Venous Leg Ulcer | - | - |
EscharEx 5% (EX-02 formulation) | Phase 2 | Superficial Basal Cell Carcinoma | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply